Chen IM, Johansen JS, Theile S, Silverman LM, Pelz KR, Madsen K, Dajani O, Lim KZM, Lorentzen T, Gaafer O, Koniaris LG, Ferreira AC, Neelon B, Guttridge DC, Ostrowski MC, Zimmers TA, Nielsen D (2025)
Erratum: Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Advanced Pancreatic Cancer: Survival and Cachexia
J Clin Oncol, JCO2501631 (in press)
DOI 10.1200/JCO-25-01631, PubMed 40700669

Sorbye H, Hjortland GO, Vestermark LW, Ladekarl M, Svensson J, Sundlöv A, Janson ET, Garresori H, Hofsli E, Kersten C, Elvebakken H, Pfeiffer P, Morken S, Assmus J, Lothe IMB, Tabaksblat E, Knigge U, Couvelard A, Perren A, Langer SW (2025)
Correction: Characteristics and treatment outcome in a prospective cohort of 639 advanced high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). The NORDIC NEC 2 study
Br J Cancer (in press)
DOI 10.1038/s41416-025-03095-1, PubMed 40659859

Skipar K, Ørvik MS, Evers C, Balteskard L, Ekanger C, Giske LE, Ødegaard K, Østrem EH, Nordstrand CS, Tøndel H, Nieder C, Guren MG, Kaasa S, Ragnum HB (2025)
Palliative radiotherapy in symptomatic pelvic soft tissue tumors (PallSoft)- protocol for a national, randomized, non-inferiority study
BMC Cancer, 25 (1), 1051
DOI 10.1186/s12885-025-14424-1, PubMed 40597814